Paper Details

  1. Home
  2. Paper Details

Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.

Author: AhrénBo, CarrMolly C, JohnsonSusan, MalloryJason, MurphyKaren, PerkinsChristopher, RendellMarc, WilsonTimothy

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This review of 7 phase 3 clinical trials examined the safety of albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in patients with type 2 diabetes mellitus (T2DM). The review found that albiglutide was well-tolerated and had similar rates of adverse events compared to other T2DM medications. However, albiglutide was associated with higher rates of diarrhea and injection-site reactions.
Paper Details　
Original Abstract of the Article :
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) stimulate the incretin system and lower glycaemic parameters in type 2 diabetes mellitus (T2DM). This analysis of clinical studies of up to 3years evaluated the safety of albiglutide, a GLP-1 RA, in people with T2DM. METHODS: Integrated sa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.diabres.2017.02.017

データ提供：米国国立医学図書館（NLM）

Safety Profile of Albiglutide for Type 2 Diabetes

This research embarks on a journey to assess the safety of albiglutide, a medication used to treat type 2 diabetes. It's like exploring a vast desert, where we need to understand the terrain and potential challenges to ensure a safe passage. This integrated safety analysis combined data from seven phase 3 clinical trials involving albiglutide compared with placebo and other diabetes medications. This comprehensive approach, much like a seasoned explorer mapping a complex landscape, helps us understand the safety profile of this drug.

The study found that albiglutide generally had a similar safety profile to other diabetes medications. This is like finding a reliable path through the desert – it provides reassurance for patients and clinicians. However, albiglutide was associated with higher rates of diarrhea and injection-site reactions compared to other medications. It's important to be aware of these potential side effects, just as we would be cautious of hidden sandstorms in a desert journey. Pancreatitis, a serious condition, occurred more often with albiglutide, highlighting the need for close monitoring and early intervention.

Understanding the Risks and Benefits

This study underscores the importance of carefully evaluating the safety of new medications. It's like navigating a desert, where each step requires careful consideration and planning. We need to weigh the potential benefits of a medication against the potential risks and make informed decisions based on a thorough understanding of the safety profile.

Managing Diabetes Safely

This research provides valuable information for patients with type 2 diabetes and their healthcare providers. It emphasizes the importance of considering the potential side effects of medications and working closely with healthcare professionals to manage diabetes safely and effectively. It's like having a knowledgeable guide on a desert journey – we need to rely on expertise and evidence-based approaches to navigate this complex health challenge.

Dr.Camel's Conclusion

This comprehensive safety analysis of albiglutide offers valuable insights for patients and clinicians alike. It's like having a detailed map of a vast desert – it helps us understand the potential challenges and navigate the treatment journey safely and effectively. While albiglutide appears generally safe, the study highlights the importance of vigilant monitoring for potential side effects and working collaboratively with healthcare professionals to manage diabetes effectively. It's a reminder that even in the most challenging terrains, careful planning and attention to detail can lead to a successful journey.

Date :
  1. Date Completed 2017-06-26
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28284167

DOI: Digital Object Identifier

10.1016/j.diabres.2017.02.017

Related Literature

Article Analysis
・Side Effects of albiglutide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.